Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Exsilio's technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates. Exsilio uses predictive in silico modeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells. Because Exsilio's medicines are encoded in mRNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/25/24 | $82,000,000 | Series A |
Arc Ventures Deep Insight Delos Capital  Innovation Endeavors Insight Partners Invus Novartis Venture Funds OrbiMed US | undisclosed |
